Related Experiment Video
Updated: May 17, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
930
Comparable Clinical Effectiveness of Baricitinib and Filgotinib in Patients With Rheumatoid Arthritis
Hironobu Kosugiyama1,2, Shuji Asai1, Kenya Terabe1
1Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
International Journal of Rheumatic Diseases
|May 16, 2025
Summary
Baricitinib and filgotinib show similar effectiveness and drug retention for rheumatoid arthritis (RA) patients over 24 weeks. Both treatments significantly reduced disease activity, with comparable outcomes between the two drugs.
Area of Science:
- Rheumatology
- Pharmacology
- Clinical Medicine
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease.
- Janus kinase (JAK) inhibitors like baricitinib and filgotinib are used to treat RA.
- Comparative effectiveness data for these agents is crucial for clinical decision-making.
Purpose of the Study:
- To compare the clinical effectiveness and drug retention of baricitinib versus filgotinib in rheumatoid arthritis (RA) patients.
- To evaluate the impact of these treatments on disease activity over a 24-week period.
Main Methods:
- Retrospective study of 101 patients on baricitinib and 103 on filgotinib (2020-2023).
- Kaplan-Meier curves and log-rank tests for drug retention.
- Paired t-tests and generalized estimating equations for Clinical Disease Activity Index (CDAI) score changes.
Main Results:
- No significant differences in drug retention rates due to ineffectiveness or adverse events between baricitinib and filgotinib.
- Both drugs significantly decreased CDAI scores from baseline over 24 weeks (p < 0.001).
- Comparable CDAI scores and remission rates were observed between the baricitinib and filgotinib groups at all evaluated time points.
Conclusions:
- Baricitinib and filgotinib exhibit comparable drug retention and clinical effectiveness in managing rheumatoid arthritis.
- Both JAK inhibitors provide significant disease activity reduction in RA patients over 24 weeks.
- These findings support the similar therapeutic roles of baricitinib and filgotinib in RA treatment.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
103
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
103
01:20The JAK-STAT Signaling Pathway
8.5K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.5K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
109
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
109
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
91
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
91
01:22Dose-Response Relationship: Potency and Efficacy
4.1K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.1K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
82
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
82